Literature DB >> 4436437

Competitive binding of bilirubin and drugs to human serum albumin studied by enzymatic oxidation.

R Brodersen.   

Abstract

The mechanism of drug-induced displacement of bilirubin from the blood into tissues was studied. A model of simple, competitive binding of bilirubin and drug to one site on serum albumin was established. Variations of the free bilirubin concentration after addition of drugs were studied in vitro by measuring velocities of oxidation with hydrogen peroxide and horseradish peroxidase. In all cases, the results were in agreement with the model. The competitive effects of 20 drugs were measured and expressed quantitatively as binding constants to the bilirubin site on human serum albumin. Several drugs caused changes of the bilirubin-albumin light absorption spectrum, indicating simultaneous binding of both ligands, without an effect on the free bilirubin concentration. Noncompetitive site-to-site effects on bilirubin binding could not be demonstrated. An equation is proposed for calculation of the maximal displacing effect of a drug from knowledge of its plasma concentration, the above-determined binding constant, and the degree of protein binding of the drug. Comparison of these results with previous observations of bilirubin displacement in newborn humans and in experimental animals indicates a general agreement with a simple competitive mechanism of binding of bilirubin and drug to one site on the albumin molecule. Binding of drugs to other, noncompetitive sites is common.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4436437      PMCID: PMC301690          DOI: 10.1172/JCI107882

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

1.  Kernicterus in premature infants associated with low concentrations of bilirubin in the plasma.

Authors:  R C HARRIS; J F LUCEY; J R MACLEAN
Journal:  Pediatrics       Date:  1958-06       Impact factor: 7.124

Review 2.  Drugs and bilirubin.

Authors:  M M Thaler; R Schmid
Journal:  Pediatrics       Date:  1971-05       Impact factor: 7.124

Review 3.  The binding of drugs by plasma proteins.

Authors:  M C Meyer; D E Guttman
Journal:  J Pharm Sci       Date:  1968-06       Impact factor: 3.534

4.  Reserve albumin binding capacity, salicylate saturation index, and red cell binding of bilirubin in neonatal jaundice.

Authors:  D Bratlid
Journal:  Arch Dis Child       Date:  1973-05       Impact factor: 3.791

5.  Chemical modification of the high-affinity bilirubin-binding site of human-serum albumin.

Authors:  C Jacobsen
Journal:  Eur J Biochem       Date:  1972-06-09

6.  Drug interactions. II. Drugs, the newborn infant, and the binding of bilirubin to albumin.

Authors:  L Stern
Journal:  Pediatrics       Date:  1972-06       Impact factor: 7.124

7.  Bilirubin colloid formation in neutral aqueous solution.

Authors:  R Brodersen; J Theilgaard
Journal:  Scand J Clin Lab Invest       Date:  1969-12       Impact factor: 1.713

8.  Structural studies and organic ligand-binding properties of bovine plasma albumin.

Authors:  T P King; M Spencer
Journal:  J Biol Chem       Date:  1970-11-25       Impact factor: 5.157

9.  Fixed drug combinations and the displacement of bilirubin from albumin.

Authors:  D Schiff; G Chan; L Stern
Journal:  Pediatrics       Date:  1971-07       Impact factor: 7.124

10.  Sulfonamides competing with bilirubin for conjugation to albumin.

Authors:  B Josephson; P Furst
Journal:  Scand J Clin Lab Invest       Date:  1966       Impact factor: 1.713

View more
  25 in total

Review 1.  The blood-brain barrier and bilirubin encephalopathy.

Authors:  R P Wennberg
Journal:  Cell Mol Neurobiol       Date:  2000-02       Impact factor: 5.046

2.  The possible risk of bilirubin encephalopathy as predicted by plasma parameters in neonates with previous severe asphyxia.

Authors:  F Ebbesen; A Knudsen
Journal:  Eur J Pediatr       Date:  1992-12       Impact factor: 3.183

3.  Calorimetric and binding dissections of HSA upon interaction with bilirubin.

Authors:  Z Moosavi-Movahedi; S Safarian; M Zahedi; M Sadeghi; A A Saboury; J Chamani; H Bahrami; A Ashraf-Modarres; A A Moosavi-Movahedi
Journal:  Protein J       Date:  2006-04       Impact factor: 2.371

Review 4.  Twenty-five years of progress in bilirubin metabolism (1952-77).

Authors:  B H Billing
Journal:  Gut       Date:  1978-06       Impact factor: 23.059

5.  Principles of a competitive binding assay for the study of the interactions of poorly water-soluble ligands with their soluble binding partners. Application to bilirubin with the use of Sephadex G-10 as a competitive adsorbent.

Authors:  J A Meuwissen; M Kinnaert; G Michiels; K P Heirwegh
Journal:  Biochem J       Date:  1988-01-01       Impact factor: 3.857

6.  Interaction between two dicarboxylate endogenous substances, bilirubin and an uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, on human serum albumin.

Authors:  Y Tsutsumi; T Maruyama; A Takadate; M Goto; H Matsunaga; M Otagiri
Journal:  Pharm Res       Date:  1999-06       Impact factor: 4.200

7.  In vitro protein binding of cefonicid and cefuroxime in adult and neonatal sera.

Authors:  J M Benson; F D Boudinot; A T Pennell; F E Cunningham; J T DiPiro
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

Review 8.  Neonatal bilirubin toxicity. A review of kernicterus and the implications of drug-induced bilirubin displacement.

Authors:  P C Walker
Journal:  Clin Pharmacokinet       Date:  1987-07       Impact factor: 6.447

9.  Protein binding of anthraquinone glycosides, with special reference to adriamycin.

Authors:  S Eksborg; H Ehrsson; B Ekqvist
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

10.  Ceftriaxone--bilirubin-albumin interactions in the neonate: an in vivo study.

Authors:  E Martin; S Fanconi; P Kälin; C Zwingelstein; C Crevoisier; W Ruch; R Brodersen
Journal:  Eur J Pediatr       Date:  1993-06       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.